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Abstract
Background: The IeDEA West Africa Pediatric Working Group (pWADA) was established in January 2007 to study
the care and treatment of HIV-infected children in this region. We describe here the characteristics at antiretroviral
treatment (ART) initiation and study the 12-month mortality and loss-to-program of HIV-infected children followed
in ART programs in West Africa.
Methods: Standardized data from HIV-infected children followed-up in ART programs were included. Nine clinical
centers from six countries contributed to the dataset (Benin, Côte d’Ivoire, Gambia, Ghana, Mali and Senegal).
Inclusion criteria were the followings: age 0-15 years and initiated triple antiretroviral drug regimens. Baseline time
was the date of ART initiation. WHO criteria was used to define severe immunosuppression based on CD4 count
by age or CD4 percent < 15%. We estimated the 12-month Kaplan-Meier probabilities of mortality and loss-to-
program (death or loss to follow-up > 6 months) after ART initiation and factors associated with these two
outcomes.
Results: Between June 2000 and December 2007, 2170 children were included. Characteristics at ART initiation
were the following: median age of 5 years (Interquartile range (IQR: 2-9) and median CD4 percentage of 13% (IQR:
7-19). The most frequent drug regimen consisted of two nucleoside reverse transcriptase inhibitors and one non-
nucleoside reverse transcriptase inhibitors (62%). During the first 12 months, 169 (7.8%) children died and 461
(21.2%) were lost-to-program. Overall, in HIV-infected children on ART, the 12-month probability of death was 8.3%
(95% Confidence Interval (CI): 7.2-9.6%), and of loss-to-program was 23.1% (95% CI: 21.3-25.0%). Both mortality and
loss-to program were associated with advanced clinical stage, CD4 percentage < 15% at ART initiation and year
(> 2005) of ART initiation.
Conclusion: Innovative and sustainable approaches are needed to better document causes of death and increase
retention in HIV pediatric clinics in West Africa.
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Pediatric HIV infection is a worldwide public health
challenge that disproportionately affects children in
the poorest parts of the world. By December 2008, an
estimated 33.4 million people were living with HIV,
2.1 million of whom were children under 15 years of
age [1]. Furthermore, 16% of the 2.7 million new HIV
infections in 2008 occurred in children [1]. At the
end of 2009, 356,400 HIV-infected children younger
than 15 years of age in low- and middle-income
countries received antiretroviral therapy (ART) repre-
senting 28% of those in need of ART with a substan-
tial variation within African region (12% in Western
and Central Africa and 32% in Eastern and Southern
Africa) [2].
Data from ongoing randomized clinical trials and
observational datasets in Africa have demonstrated a
clear mortality benefit from starting ART among chil-
dren eligible for ART [3-9]. However, in sub-Saharan
Africa, the daily management of HIV care for children
remains a great challenge for the following reasons:
first, diagnosing HIV infection early among children
less than 18 months is difficult; second, human
resources trained to deliver ART to children are lack-
ing; third, pediatric antiretroviral formulations are lim-
ited; fourth, ART is complex in the context of multiple
co-morbidities (tuberculosis, malaria, malnutrition,
etc.); and lastly, low-income countries suffer from poor
health care systems [2,10,11]. In spite of these chal-
lenges, data from various pediatric ART programs in
Africa report good early clinical outcomes in children
[3-5,8]. In adult cohorts, the poor retention, varied
between 76-80%, was reported at 12 months in HIV
care among patients initiated ART [12-14]. Few reports
on retention in pediatric care are available in sub-
Saharan Africa.
In July 2006, the National Institute of Health
launched the International epidemiological Database
to Evaluate AIDS (IeDEA) initiative to better describe
the trends of the epidemiology of HIV in the context
of ART access in specific regions in the world http://
www.iedea-hiv.org In West Africa http://www.iedea-
westafrica.org, the IeDEA Pediatric Working Group
(pWADA) was established in January 2007 to study
the care and treatment of HIV-infected children in
this region of sub-Saharan Africa, where the ART cov-
erage among children reported in 2009 was the lowest
(12%) [2].
In this context, we aimed to describe the characteris-
tics of HIV-infected children at ART initiation and
study the 12-month mortality and loss-to-program rates
in the pWADA database.
Methods
The IeDEA West Africa collaboration
By collecting and integrating data from multiple HIV/
AIDS cohorts, this initiative aims to address unique and
evolving research questions in the field of HIV/AIDS
care and treatment. In West Africa, this collaboration
was initiated in July 2006 and currently involves 10
pediatric HIV/AIDS clinics spread over eight countries.
The first merger, done in April 2008, included the data
from nine pediatric clinical centers in Benin (n = 1),
Côte d’Ivoire (n = 4), Gambia (n = 1), Ghana (n = 1),
Mali (n = 1) and Senegal (n = 1).
Inclusion criteria
In the IeDEA West Africa pediatric HIV center, clinical
forms were available for recording HIV activities and an
electronic database was available for data entry. We
used a standardized data collection procedure to merge
the HIV pediatric data [15]. All HIV-1-infected children
(positive viral load test < 18 months or positive serology
≥ 18 months) aged < 16 years with documented gender
and initiated triple drugs antiretroviral therapy were
included irrespective of the first-line ART regimens.
The initiation of ART was based on the national or
international guidelines [11,16,17].
The following information was recorded in the
d a t a b a s e :a g e ,g e n d e r ,b o d ym a s si n d e x ,d a t eo fA R T
initiation, pre-treatment CD4 percentage, cotrimoxazole,
initiation and type of ART regimens. HIV-infected chil-
dren are typically seen in clinics at least every three
months, and their CD4 counts are measured twice a
year to monitor their immunological response to ART.
Routine viral load monitoring is not available in most
sites.
Ethical aspects
The IeDEA West Africa collaboration was approved by
the national ethics committees of each country. Indivi-
dual informed signed consent was waived for this
analysis.
Outcomes
The outcomes of this study were i) death, defined as any
death recorded in the database during the first year of
follow-up; ii) loss-to-follow-up, indicated when the
interval between the last clinic visit registered in the
database and the closing date of the database was > 6
months; and iii) loss-to-program, defined as the com-
bined outcome of death or loss-to-follow-up.
The baseline was the date of ART initiation. The expla-
natory variables included the following: gender, age at
ART initiation, 2006 WHO criteria for immunodeficiency
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[17], cotrimoxazole status at ART initiation, year of ART
initiation and first-line antiretroviral regimen (Non-
Nucleoside Reverse Transcriptase Inhibitor [NNRTI] or
Protease Inhibitor [PI]). The clinical stage of the disease
was defined as either less advanced (CDC stage A/B or
WHO stage I/II/III/) or advanced (CDC stage C or
WHO stage IV).
Statistical analysis
Continuous variables were compared using the Wil-
coxon rank-sum test, and comparisons between two
categorical variables were performed using the Chi-
square test and Fisher’s exact test when appropriate.
The Kaplan-Meier method was used to estimate the
probability of death or loss to program with their 95%
Confidence Interval (CI). The logrank test was used for
comparisons between groups. We used Weilbull regres-
sion models with random effects to estimate mortality
and loss-to-program hazard ratios (HR) with their 95%
CI, accounting for heterogeneity between the different
programs or cohorts. Models included individual vari-
ables (age, sex, pre-ART CD4 count, type of initial regi-
men and clinical stage of disease, cotrimoxazole
initiation and year of ART initiation). The multivariable
analysis was performed by the backward selection proce-
dure including all variables (explicative model). The
dataset was closed for analysis after the data merger was
completed in April 2008. Follow-up was censored at the
date of death for children deceased or the date of the
last visit for children who were lost to follow-up.
Children alive and in care in April 2008 were right-cen-
sored at the date of their last visit before this fixed date.
All analyses were performed using intent-to-treat
approach with SAS software version 9.1 (SAS Institute,
Cary, NC, USA).
Results
Description of sites
The collaboration included nine pediatric clinical cen-
ters from six countries in West Africa (Table 1). Free
access to all laboratory tests (CD4 count testing, liver
function testing and total blood count) was available in
t h r e eo u to ft h en i n ec l i n i c a lc e n t e r s( T a b l e1 ) .A l lo f
the children had free access to ART as well as cotrimox-
azole prophylaxis expected at the Korbelu Teaching
Hospital in Ghana. Four of the clinical centers are
located within teaching hospitals. The biggest cohort
was located in Bamako, with 673 ART-treated children,
and the smallest site was in Gambia, with 23 children
enrolled (Table 2).
Characteristics of patients and antiretroviral regimens at
ART initiation
Between June 2000 and December 2007, 2,170 children
were included. The baseline characteristics per center
are summarized in table 2. Overall, median age was 5
years (Interquartile range [IQR]: 2-9); median CD4 per-
centage was 13% (IQR: 7-19); and 51.8% of these HIV-
infected children had immunosuppression at ART initia-
tion. All of the sites had similar baseline characteristics
except for the MTCT-Plus clinic, which recruited
Table 1 Characteristics of the paediatric clinical sites in the IeDEA West African collaboration (pWADA), 2000-2007.
Country Site Electronic files
or medical
records
Location Sector
(public/
private)
Free
access
to ART
Free access
to
cotrimoxazole
Free
access to
lab exams*
Availability of tracing
methods for loss to
follow-up**
Benin Hôpital d’Instruction des
Armées, Cotonou (UPEIV)
Electronic Urban Private Yes Yes Yes Yes
Côte
d’Ivoire
Centre de Prise en charge, de
Recherche et de Formation
(CEPREF), Abidjan
Electronic Urban Public Yes Yes Yes Yes
Côte
d’Ivoire
MTCT Plus Network, Abidjan Electronic Urban Public Yes Yes Yes Yes
Côte
d’Ivoire
CHU de Yopougon, Abidjan Electronic Urban Public Yes Yes Yes Yes
Côte
d’Ivoire
CIRBA Electronic Urban Semi-
public
Yes Yes Yes No
Gambia Medical Research Council, Fajara Medical
records
Urban Public Yes Yes Yes No
Ghana Korle Bu Hospital, Accra (KBTH) Medical
records
Urban Public No No Yes No
Senegal Hôpital d’Enfants Albert-Royer,
Dakar
Medical
records
Urban Public Yes Yes Yes Yes
Mali Hôpital Gabriel Touré, Bamako Electronic Urban Public Yes Yes Yes No
* Free access to laboratory exams (CD4 count testing, total blood count, liver function testing)
**Tracing methods: used cell phone call or do home visit by social workers team when the patient missed one scheduled visit
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higher median CD4 percentage (18%). Cotrimoxazole
was initiated in 27.2% of children (range: 0.0%-98.6%).
The first-line treatment combinations were two nucleo-
side reverse transcriptase inhibitors (NRTI) and one
non-nucleoside reverse transcriptase inhibitor (NNRTI)
in 62.0% of the cases, followed by two NRTIs and one
protease inhibitor (PI) in 36.3% of cases, and the other
combinations were used in 1.7% of the cases. The most
frequent PI used was Nelfinavir (95.7%); the remaining
cases were treated with Lopinavir boosted with
Ritonavir.
Mortality rate and loss-to-program
Among these 2,170 HIV-infected children on ART, 169
(7.8%) died during the follow-up period (1761 child-
years) with a mortality rate, estimated to be 9.6 deaths
per 100 child-years (95% CI: 9.4-9.7). Overall, the 12-
month probability of death after ART initiation was
8.3% (95% CI: 7.2-9.6%), with substantial differences
across sites and age categories (p = 0.001) (Table 3).
The 12-month probability of death was 11.0% in chil-
dren with severe immunosuppression (CD4 percentage
< 15%) at baseline, 2.7% in those with CD4 percentage ≥
15% and 9.3% in those with unknown CD4 percentage
(p < 0.0001) (Figure 1).
The 12 month probability of lost-to follow-up was
16.0% (95% CI: 14.4-17.8%), and varied according to age
group (Table 3).
A total of 461 children were lost-to-program (dead
or last visit > 6 months) with an incidence of 26.2 per
100 child-years, 95% CI [25.9-26.4]. The 12-month
probability of loss-to-program on ART were 23.1%
(95% CI: 21.3-25.0%) overall and varied per age group
(p = 0.0005) (Table 3). This probability was 21.2% for
a CD4 percentage < 15%, 10.8% for a CD4 percentage
≥ 1 5 %a n d3 0 . 5 %f o rm i s s i n gC D 4p e r c e n t a g e( p<
0.0001).
Factors associated with death or loss-to-program
A multivariable analysis was performed adjusting for
gender, age, type of ART regimen, clinical stage, CD4
percentage of ART initiation, year of ART initiation,
and cotrimoxazole status. The adjusted hazard ratio
(aHR) of death was 2.1 (95% CI: 1.1-4.1) for children
with CD4 percentage < 15%. It was 1.5 (95% CI: 0.6-
3.6) for those with a missing CD4 percentage (refer-
ence group was CD4≥ 15% at ART initiation). The
Table 2 Baseline characteristics at antiretroviral treatment (ART) initiation of 2170 children.
Site N Girl
(%)
Median
Age
(years)
(IQR)
%AIDS or
clinical
stage IV (%
Missing)
Initial ART regimen (%) Median
CD4 cell
count
(IQR)
Median
CD4
percent
(IQR)
%Immuno-
supression*
(%Missing)
%CTX
Status
$
(%
Missing)
Year of ART
initiation
2NRTI
+1NNRTI
2NRTI
+1 PI
Others ≤
2004
2005 ≥
2006
UPEIV 71 46.5 4 (2-7) 24.3 (1.4) 0.0 100.0 0.0 291
(132-517)
8(5-12) 89.9 (2.8) 100.0
(1.4)
50.7 19.7 29.6
CEPREF 306 42.5 6 (3-9) 20.2 (1.6) 63.1 33.3 3.6 356
(106-728)
11 (6-16) 79.5 (15.4) 32.8 (0.3) 12.7 50.7 36.6
MTCT
Plus
74 52.7 2 (1-4) 10.3 (21.6) 35.1 64.9 0.0 858
(437-1285)
18
(14-24)
57.7 (4.1) 89.7
(21.6)
41.9 23.0 35.1
CHU
Yopougon
650 48.3 6(3-10) 0.5 (4.0) 46.0 53.5 0.5 445
(201-738)
14(7-21) 60.1 (14.5) 15.6 (0.6) 52.3 24.2 23.5
CIRBA 141 47.5 4 (2-7) 53.3 (5.1) 66.7 31.9 1.4 393
(227-947)
14 (6-20) 72.0 (46.8) 71.2
(48.2)
13.5 19.9 66.7
FAJARA 23 47.8 6 (4-12) - (100.0) 82.6 13.0 4.3 305
(220-580)
15 (9-19) 50.0 (4.3) - (100.0) 4.3 34.8 60.9
KBTH 128 47.7 6 (3-8) 3.9 (0.0) 96.9 0.0 3.1 332
(77-684)
11 (4-17) 65.6 (25.0) 93.8 (0.0) 11.7 51.6 36.7
Albert
Royer
104 43.3 7 (4-10) 55.3 (1.0) 81.7 15.4 2.9 340
(31-610)
9 (4-15) 63.9 (41.3) 92.3 (0.0) 32.7 20.2 47.1
Gabriel
Toure
673 40.4 4 (2-8) 30.4 (2.2) 75.2 23.0 1.8 335
(115-602)
- 55.8 (16.3) - (100.0) 39.8 18.0 42.2
Total 2170 44.8 5 (2-9) 19.1 (13.2) 62.0 36.3 1.7 385
(142-691)
13
(7-19)
63.4 (18.3) 42.7
(36.2)
36.0 27.1 36.9
IeDEA paediatric West Africa database (pWADA), 2000-2007.
IQR: Interquartile range, NRTI: Nucleoside reverse transcriptase inhibitors, NNRTI: Non nucleoside reverses transcriptase inhibitors,
PI: protease inhibitors, KBTH: Korlebu Teaching Hospital, Accra, UPEIV: Hôpital d’Instruction des armées, Cotonou, CTX: Cotrimoxazole
* According to WHO definition [4], $ at ART initiation
Ekouevi et al. BMC Public Health 2011, 11:519
http://www.biomedcentral.com/1471-2458/11/519
Page 4 of 10aHR was 2.5 (95% CI: 1.6-3.9) for children at an
advanced clinical stage at ART initiation. For children
who initiated ART in 2005, the aHR was 1.7 (95% CI:
1.0-2.9) compared to those who initiated ART before
2005. The aHR was 2.8 (95% CI: 1.7-4.7) for children
who initiated ART in 2006 or after. The remaining
variables such as gender, age, first-line ART regimen
and cotrimoxazole status were not independently asso-
ciated with death (Table 4).
Similar factors were associated with loss-to-program
(Table 5): advanced clinical stage (aHR = 2.3, 95% CI
(1.7-3.0)); CD4 percentage < 15% (aHR = 1.9, 95% CI
(1.3-2.9)); and year of ART initiation. The aHR for chil-
dren who initiated ART in 2005 was 1.7 (95% CI: 1.3-
y
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0369 1 2
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0369 1 2
(A)  (B) 
 
Baseline: at ART initiation  
Percentage of 
CD4 at baseline 
Month-6    Month-12    Month-6    Month-12 
Children 
at risk 
Probability 
(95% CI) 
  Children 
at risk 
Probability 
(95% CI) 
  Children 
at risk 
Probability 
(95% CI)   
Children 
at risk 
Probability 
(95% CI) 
<15%    531  9.4 (7.4;.12.0)      439  11.0 (8.8; 13.8)    531  14.6 (12.2; 17.6)    439  21.2 (18.2; 24.6) 
≥15%    417  2.2 (1.2; 4.0)      372  2.7 (1.5; 4.7)    417  5.2 (3.5; 7.7)    372  10.8 (8.2; 14.1) 
Unknown    832  6.9 (5.5; 8.7)      562  9.3 (7.6; 11.4)    832  10.0 (8.3; 12.0)    562  30.5 (27.5; 33.6) 
Log Rank test: p < 0.0001 
<15%   Percentage of CD4  Unknown  + 15% 
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
D
e
a
t
h
 
Time (months) 
Log Rank test: p < 0.0001 
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
D
e
a
t
h
+
l
o
s
t
 
t
o
 
f
o
l
l
o
w
-
u
p
 
Time (months) 
Percentage of CD4  <15%   Unknown  + 15% 
Figure 1 Kaplan-Meier probability of death (A) or loss to program (death or loss to follow-up) (B) in 2170 children on antiretroviral
therapy (ART), by CD4 percentage at ART initiation. IeDEA pediatric West Africa database (pWADA), 2000-2007.
Table 3 Probability of death or loss to program in 2170 children on antiretroviral therapy (ART), by age group at ART
initiation.
Death Loss to follow-up Loss to program (death and
lost to follow-up)
Month-6 Month-12 Month-6 Month-12 Month-6 Month-12
Age at ART initiation n Probability
(95% CI)
n Probability
(95% CI)
n Probability
(95% CI)
n Probability
(95% CI)
n Probability
(95% CI)
n Probability
(95% CI)
< 12 months 36 8.9
(3.4; 22.2)
23 11.7
(5.0; 26.0)
36 0.0
(0.0; 0.0)
23 20.2
(10.2; 37.8)
36 8.9
(3.4;.22.2)
23 29.8
(18.0; 46.6)
1-3 years 398 10.6
(8.2; 13.7)
278 12.7
(10.0; 16.1)
398 5.0
(3.4; 7.3)
278 19.4
(15.8; 23.7)
398 15.1
(12.2; 18.5)
278 29.7
(25.7; 34.1)
3-5 years 341 3.7
(2.2; 6.2)
262 5.2
(3.4; 8.1)
341 2.4
(1.2; 4.6)
262 15.9
(12.3; 20.3)
341 6.0
(4.0; 8.9)
262 20.3
(16.5; 24.9)
5-10 years 629 5.6
(4.2; 7.5)
516 7.1
(5.4; 9.2)
629 4.2
(3.0; 6.0)
516 13.8
(11.4; 16.8)
629 9.6
(7.7; 12.0)
516 19.9
(17.1; 23.1)
≥ 10 years 376 6.2
(4.3; 8.9)
294 8.1
(5.9; 11.2)
376 4.3
(2.7; 6.7)
294 15.8
(12.5; 19.9)
376 10.2
(7.7; 13.5)
294 22.7
(18.9; 27.0)
IeDEA pediatric West Africa database (pWADA), 2000-2007.
n: number of children at risk
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Page 5 of 102.4), and the aHR for those who initiated ART in 2006
and after was 3.0 (95% CI: 2.2-4.0) compared to those
who initiated ART before 2005
Discussion
The IeDEA West Africa collaboration provides an
opportunity to collect, analyze and compare access to
ART and its field outcomes in this part of the world.
After one year on ART, the overall mortality in children
was 8.3% and the retention in HIV care programs was
78.8%. The same factors were independently associated
with both death and retention in HIV care: an advanced
HIV disease, a severe immunosuppression at ART initia-
tion and year of ART initiation.
Similar mortality rates was reported in other studies
conducted with HIV-infected children in Africa and,
ranging from 6.3% to 11.5% [3,5,7,8,18]. The mortality
rate reported in the studied cohorts is likely under-esti-
mated because there was a high rate of loss-to-follow-up
in the HIV cohort and lost to follow-up children were
severely immune-suppressed, a marker of a higher risk
of death. In general, mortality is under-estimated in
ART African programs because of the misclassification
of LTFU [12,19,20]. An investigation conducted in adult
patients LTFU in Malawi found that 50% of them had
died, 23% were alive and 27% untraceable [21]. We were
not able to classify patients LTFU as their status was
not routinely ascertained in the participating centers.
All the participating cohorts reported a late access to
ART, except the Abidjan MTCT-Plus group, in which
the linkage between PMTCT and HIV postnatal care
has been strengthened by early HIV pediatric diagnosis.
In the MTCT-Plus group, the median age at ART initia-
tion was 2 years [22]. Indeed, in the current study, only
Table 4 Weibull survival model with random effects in 2131 children on antiretroviral therapy (ART).
Univariate analysis Multivariate analysis
HR* 95% CI P aHR 95% CI P
Sex
Boys 1 - - 1 - -
Girls 1.1 0.7-1.5 0.72 1.0 0.7-1.4 0.88
Age at ART initiation
10 years and plus 1 - - 1 - -
[5-10] years 0.8 0.5-1.4 0.49 0.9 0.5-1.5 0.70
[3-5] years 0.6 0.3-1.2 0.15 0.9 0.5-1.7 0.68
[1-3] years 1.5 0.9-2.6 0.12 1.2 0.7-2.1 0.40
< 12 months 1.2 0.4-4.3 0.69 1.1 0.3-3.8 0.79
ART regimen at baseline
2 NRTI+1 NNRTI 1 - - 1
2 NRTI+1 PI 0.7 0.4-1.0 0.06 0.9 0.6-1.5 0.76
Other 0.2 0.02-2.6 0.21 1.0 0.2-5.0 0.98
Clinical stage at ART initiation
A, B or I, II, III 1 - - 1 - -
AIDS or IV 6.0 3.9-9.2 < 0.01 2.5 1.6-3.9 < 0.01
Unknown 0.9 0.4-2.0 0.90 1.4 0.7-2.9 0.29
% CD4 at ART initiation
≥ 15% 1 - - 1 - -
< 15% 2.1 1.1-3.9 0.02 2.1 1.1-4.1 0.03
Missing 1.5 0.7-3.3 0.22 1.5 0.6-3.6 0.27
Year of ART initiation
≤ 2004 1 - - 1 - -
2005 1.8 1.0-3.0 0.03 1.7 1.0-2.9 0.04
≥ 2006 2.6 1.7-4.2 < 0.01 2.8 1.7-4.7 < 0.01
Initiation of cotrimoxazole at ART initiation
No 1 - - 1 - -
Yes 1.3 0.7-2.5 0.39 0.9 0.5-1.7 0.67
Missing 0.6 0.1-3.1 0.50 0.4 0.1-2.3 0.30
IeDEA paediatric West Africa database (pWADA), 2000-2007. Mortality analysis.
*HR = Hazard Ratio, **95% CI = 95% Confidence Interval, aHR = adjusted Hazard Ratio
Heterogeneity between cohort, p = 0.25
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Page 6 of 102% of children initiated ART before their first year age.
This observation is consistent with data reported by
MSF programs, which reported that only 8.5% of chil-
dren were less than 12 months at ART initiation [8].
Our findings underline important concerns in the timely
identification of HIV-infected children in urban areas of
West Africa. The linkage between the PMTCT program
and pediatric care is crucial and should be reinforced
wherever possible to identify HIV-infected infants earlier
[22]. Substantial challenges in pediatric care in low-
income countries include identifying HIV-infected chil-
dren earlier and initiating ART treatment as quickly as
possible. The access to an early infant diagnostic for
HIV by PCR remains largely uncommon [23,24]. Despite
the recent availability of dried blood spots testing,
including in rural areas [23-25], the delay between HIV
testing and availability of the results remains a concern
and requires particular organization. In 2009, only 15%
of children born to HIV-positive mothers received an
HIV test within the two first two months of life [2].
In the current study, age was not associated with
death as reported in the KIDS-ART-LINC Collaboration
[3] and also with loss-to-program. We unquestionably
enrolled in this observational data the HIV-1 infected
long-term non-progressors who survive until 5 years as
most of HIV transmission among infants were mother-
to-child transmission. Indeed, the mortality in vertically-
infected children before the introduction of ART in the
first year of life was about 40% and less than 30% in
children infected in postnatal period [26].
We reported that 51.8% of children exhibited severe
immunosuppression at ART initiation, which was asso-
ciated with both death and loss-to-program. This asso-
ciation was previously reported for death but not for
Table 5 Weibull survival model with random effects in 2131 children on antiretroviral therapy (ART).
Univariate analysis Multivariate analysis
HR* CI (95%)** P aHR CI (95%)** P
Sex
Boys 1 - - 1 - -
Girls 1.0 0.8-1.3 0.72 1.0 0.8-1.2 0.78
Age at ART initiation
10 years and plus 1 - - 1 - -
[5-10] years 0.9 0.6-1.2 0.32 0.9 0.7-1.3 0.56
[3-5] years 0.8 0.5-1.2 0.22 0.9 0.6-1.3 0.52
[1-3] years 1.3 0.9-1.8 0.10 1.1 0.8-1.6 0.34
< 12 months 1.4 0.6-2.9 0.36 1.1 0.5-2.4 0.66
ART regimen at baseline
2 NRTI+1 NNRTI 1 - - 1
2 NRTI+1 IP 0.7 0.5-0.9 0.01 0.9 0.7-1.2 0.62
Other 0.6 0.2-1.5 0.24 1.0 0.4-2.5 0.98
Clinical stage at ART initiation
A, B or I, II, III 1 - - 1 - -
AIDS or IV 2.6 2.0-3.5 < 0.01 2.3 1.7-3.0 < 0.01
Unknown 1.3 0.8-2.1 0.21 1.4 0.9-2.3 0.15
% CD4 at ART initiation
≥ 15% 1 - - 1 - -
< 15% 2.1 1.4.3.2 < 0.01 1.9 1.3-2.9 < 0.01
Missing 1.5 0.9-2.5 0.07 1.7 1.1-2.8 0.03
Year of ART initiation
≤ 2004 1 - - 1 - -
2005 2.0 1.5-2.7 < 0.01 1.7 1.3-2.4 < 0.01
≥ 2006 3.5 2.6-4.6 < 0.01 3.0 2.2-4.0 < 0.01
Cotrimoxazole status at ART initiation
No 1 - - 1 - -
Yes 1.2 0.7-1.8 0.43 0.9 0.6-1.4 0.63
Missing 0.6 0.2-1.8 0.32 0.4 0.1-1.5 0.16
IeDEA paediatric West Africa database (pWADA), 2000-2007. Loss-to-program analysis.
*HR = Hazard Ratio, **95% CI = 95% Confidence Interval, aHR = adjusted Hazard Ratio
Heterogeneity between cohort, p = 0.14
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nostic of pediatric HIV infection in children could also
explain the severe immunosuppression observed among
HIV-infected children who initiated ART.
HIV-infected children who initiated ART in 2005 or
after presented a higher risk of death or loss-to-program
compared to children who initiated ART before 2005.
Possible explanations for this finding are as follows.
First, the children who initiated ART after 2005 were at
a more advanced clinical stage and presented more
severe immunosuppression than the children who
initiated before 2005 (data not shown). Second, there
was a substantial increase in the number of HIV-
infected children who were followed up in these centers
with an increased workload, which may have impacted
the standard of care. Indeed, we noted that the number
the children who initiated ART between 2005 and 2008
roughly doubled in this period. Third, after 2005, there
was an extension of new pediatric clinical centers with
the new initiatives and support of US partners. It sug-
gests that existing services are increasingly challenged to
cope with the increased load of HIV-infected children
due to the rapid scale up of ART programs in West
African countries.
In the current study, retention of HIV pediatric care
programs was 78.8% in West Africa at 12 months of fol-
low-up. Retention was 85% at 12 months and 75% at 36
months in the pediatric MSF programs [8]. Retention in
HIV care is now one of the most important challenges
faced by heath care workers and HIV implementing
partners as the coverage of HIV care and treatment
have improved for both adults and children in low-
income countries. Similar findings were reported in
adult patients, with a low rate (76%) of retention in HIV
care at 12 months in the IeDEA West Africa [12]. Also,
a systematic review of adult patients in low-income
countries reported that the retention in HIV care at 36
months was 64.6% [13]. Innovative and sustainable
approaches to improve retention in HIV pediatric care
are needed. For the adult’s HIV-infected patients, then
keys recommendations was proposed based on the
Malawi’s’ experience [28]. We believe that some of these
recommendations could be applied for the pediatric
HIV care.
We acknowledge that the present study is not repre-
sentative of all children on ART in West Africa as most
of the data was gathered from urban sites, in which the
standard of care may be higher than in rural areas.
However, this study allows a comparison of the manage-
ment of HIV care at the patient level between the pro-
grams in six countries in West Africa. In addition, we
hypothesize that the operational problems identified
here will be worse in less structured clinical care.
One limitation of this study, and generally in large
collaborative studies, is the lack of data collected on fac-
tors related to access to health care, such as adherence
to ART, or social variables, such as orphan status, to
better explain mortality in HIV-infected children. These
key variables are not routinely collected in the clinical
forms used in the different HIV centers. In addition, the
analysis did not include nutritional status (weight-for-
age, height-for-age) as the data available are not exploi-
table due to important missing data. Also, data on cotri-
moxazole initiation was under-reported, explaining the
low rate of children who initiated cotrimoxazole in the
collaboration. Another limitation is the quality of data
in the HIV cohort in West Africa, specifically in regards
to missing data of key variables, such as percentage of
CD4 count at baseline (47%). The quality of data col-
lected as well as its validity remains challenging in low
incomes countries. However, this merger of data pre-
sented a clear picture of the quality of data and pro-
vided an example of the challenges of gathering reliable
data in the field reality of the HIV pediatric cohorts in
West Africa. After the assessment of available data, pro-
cedures were put into place in the collaboration to
improve the quality of data in the participating centers.
There have been dramatic advances in the daily man-
agement of HIV disease in children in West Africa, with
overall good clinical outcomes but low retention rates.
The IeDEA West Africa collaboration offers the oppor-
tunity to increase the quality of data, which remains a
concern in sub-Saharan African cohort, as well as to
better document clinical outcomes. Comparisons with
other IeDEA regions of the world could improve the
understanding of the clinical outcomes reported.
Conclusions
It is urgent to find innovative approaches to early
screening of HIV-infected children from six weeks of
age onwards to implement large scale and durable
pediatric ART programs. It is also important to better
document causes of death and loss to program and to
propose sustainable approaches to increase retention in
HIV pediatric programs in West Africa.
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